December 4, 2020
Business News

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines


CAMBRIDGE, Mass.–()–Be Biopharma (“Be Bio”), a leader in developing B cells as medicines, founded by Longwood Fund, David Rawlings, MD, and Richard James, PhD, today announced a $52 million Series A financing led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc. The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at Seattle Children’s Research Institute. B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have broad,…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Cybersecurity Maturity Model Certification Accreditation Body (CMMC-AB) Announces CEO Search Through JDG Associates, Ltd.
AM Best Affirms Credit Ratings of AzRe Reinsurance, OJSC
AON Splash Image
Cybersecurity Model Maturity Certification Accreditation Body (CMMC-AB) Announces CEO Search Through JDG Associates, Ltd.